Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PBYI's Cash to Debt is ranked higher than
89% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. PBYI: No Debt )
PBYI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
PBYI's Interest Coverage is ranked higher than
68% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PBYI: No Debt )
PBYI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 217.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -65.08
PBYI's ROE (%) is ranked higher than
59% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. PBYI: -65.08 )
PBYI' s 10-Year ROE (%) Range
Min: -65.08   Max: -18.82
Current: -65.08

-65.08
-18.82
ROA (%) -52.37
PBYI's ROA (%) is ranked higher than
59% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. PBYI: -52.37 )
PBYI' s 10-Year ROA (%) Range
Min: -850   Max: -18.47
Current: -52.37

-850
-18.47
ROC (Joel Greenblatt) (%) -3256.12
PBYI's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. PBYI: -3256.12 )
PBYI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5033.81   Max: -1489.3
Current: -3256.12

-5033.81
-1489.3
EPS Growth (%) 883.00
PBYI's EPS Growth (%) is ranked higher than
100% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. PBYI: 883.00 )
PBYI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 883
Current: 883

0
883
» PBYI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PBYI Guru Trades in Q3 2013

Steven Cohen 15,800 sh (New)
» More
Q4 2013

PBYI Guru Trades in Q4 2013

Steven Cohen 5,800 sh (-63.29%)
» More
Q1 2014

PBYI Guru Trades in Q1 2014

Pioneer Investments 30,901 sh (New)
Jim Simons 12,600 sh (New)
Steven Cohen 78,938 sh (+1261%)
» More
Q2 2014

PBYI Guru Trades in Q2 2014

Jim Simons Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PBYI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 45.90
PBYI's P/B is ranked lower than
62% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. PBYI: 45.90 )
PBYI' s 10-Year P/B Range
Min: 0   Max: 47.1
Current: 45.9

0
47.1
Current Ratio 6.57
PBYI's Current Ratio is ranked higher than
82% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. PBYI: 6.57 )
PBYI' s 10-Year Current Ratio Range
Min: 0.67   Max: 91.58
Current: 6.57

0.67
91.58
Quick Ratio 6.57
PBYI's Quick Ratio is ranked higher than
83% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PBYI: 6.57 )
PBYI' s 10-Year Quick Ratio Range
Min: 0.67   Max: 91.58
Current: 6.57

0.67
91.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 51.70
PBYI's Price/Net Cash is ranked higher than
58% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PBYI: 51.70 )
PBYI' s 10-Year Price/Net Cash Range
Min: 4.69   Max: 51.72
Current: 51.7

4.69
51.72
Price/Net Current Asset Value 51.30
PBYI's Price/Net Current Asset Value is ranked higher than
57% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. PBYI: 51.30 )
PBYI' s 10-Year Price/Net Current Asset Value Range
Min: 4.39   Max: 51.72
Current: 51.3

4.39
51.72
Price/Tangible Book 46.20
PBYI's Price/Tangible Book is ranked lower than
65% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. PBYI: 46.20 )
PBYI' s 10-Year Price/Tangible Book Range
Min: 4.18   Max: 35.7
Current: 46.2

4.18
35.7
Forward Rate of Return (Yacktman) -0.29
PBYI's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. PBYI: -0.29 )
PBYI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -0.29

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PB.Germany
Puma Biotechnology Inc, a Delaware corporation was incorporated on April 27, 2007. The Company is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which it is developing for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; PB272 (neratinib (intravenous)), which it are developing for the treatment of advanced cancer patients; and PB357, which it believe can serve as a backup compound to PB272. The Company is initially focused on developing neratinib for the treatment of patients with human epidermal growth receptor type 2, or HER2, positive breast cancer. Studies show that approximately 20% to 25% of breast cancer tumors have an over-expression of the HER2 protein. Women with breast cancer that over-expresses HER2, referred to as HER2 positive breast cancer, are at greater risk for disease progression and death than women whose tumors do not over-express HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy have been developed to improve the treatment of this cancer by binding HER2. The Company licenses the exclusive worldwide rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company has modified Pfizer's clinical development strategy and during the next 12 to 18 months plan to: commence Phase III clinical trials evaluating the use of with HER2-positive metastatic breast cancer who have previously failed two or more prior treatment; continue the ongoing Phase II clinical trial of neratinib in the neoadjuvant treatment of HER2 positive breast cancer, in patients with HER2 positive metastatic breast cancer that has metastasized to the brain; and continue to evaluate the application of neratinib in the treatment of other forms of HER2 positive cancers where there may be unmet medical needs. The Company's competitors include, but are not limited to, Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide